Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Serotonergic agents in development at Lilly for CNS and other disorders

March 17, 1999

James Black Foundation describes series with antagonist or inverse agonist activity at H3 receptors

March 17, 1999

Major clinical study confirms efficacy and safety of rivastigmine in AD

March 17, 1999

NeoTherapeutics begins Neotrofin clinical trials in Canada and Australia

March 16, 1999

New salt of paroxetine with improved physicochemical characteristics

March 16, 1999

Biovail's Brexidol receives Canadian marketing approval

March 16, 1999

Novel sublingual apomorphine: efficacy and tolerability in fluctuating Parkinson's disease

March 16, 1999

Effexor XR receives FDA approval for treatment of GAD

March 15, 1999

GABA-A receptor ligands from MS&D for Alzheimer's disease

March 15, 1999

N-type calcium channel inhibitors described by Ono

March 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...